The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
L‐type calcium channel blockers and Parkinson disease in Denmark
Open accessAbstract
Objective: This study was undertaken to investigate L‐type calcium channel blockers of the dihydropyridine class for association with Parkinson disease (PD), because some of these drugs traverse the blood–brain barrier, are potentially neuroprotective, and have previously been evaluated for impact on PD risk. Methods: We identified 1,931 patients with a first‐time diagnosis for PD between 2001 and 2006 as reported in the Danish national hospital/outpatient database and density matched them by birth year and sex to 9,651 controls from the population register. The index date for cases and their corresponding controls was advanced to the date of first recorded prescription for anti‐Parkinson drugs, if prior to first PD diagnosis in the hospital records. Prescriptions were determined from the national pharmacy database. In our primary analyses, we excluded all calcium channel blocker prescriptions 2 years before index date/PD diagnosis. Results: Employing logistic regression analysis adjusting for age, sex, diagnosis of chronic pulmonary obstructive disorder, and Charlson comorbidity score, we found that subjects prescribed dihydropyridines (excludes amlodipine) between 1995 and 2 years prior to the index date were less likely to develop PD (odds ratio, 0.73; 95% confidence interval, 0.54–0.97); this 27% risk reduction did not differ with length or intensity of use. Risk estimates were close to null for the peripherally acting drug amlodipine and for other antihypertensive medications. Interpretation: Our data suggest a potential neuroprotective role for centrally acting L‐type calcium channel blockers of the dihydropyridine class in PD that should be further investigated in studies that can distinguish between types of L‐type channel blockers. ANN NEUROL 2010;67:600–606
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Danish National Hospital Register. A valuable source of data for modern health sciences.
Andersen, T. F., Madsen, M., Jørgensen, J. O. L., Mellemkjoer, L., & Olsen, J. H. (1999) · PubMed · Cited by 2,026
Self-citation‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis
Henchcliffe, C., & Beal, M. F. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0924 · Cited by 783
The Danish prescription registries.
Gaist, D., Sørensen, H. T., & Hallas, J. (1997) · PubMed · Cited by 570
Invited Article: Nervous system pathology in sporadic Parkinson disease
Braak, H., & Del Tredici, K. (2008) · Neurology · doi:10.1212/01.wnl.0000312279.49272.9f · Cited by 538
Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., Krantz, D. E., Kobayashi, K., Edwards, R. H., & Sulzer, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.033 · Cited by 534
Dysautonomia in Parkinson's disease: neurocardiological abnormalities
Goldstein, D. S. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00555-6 · Cited by 327
Calcium, ageing, and neuronal vulnerability in Parkinson's disease
Surmeier, D. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70246-6 · Cited by 297
Pharmacotherapy of Essential Tremor: An Overview of Existing and Upcoming Agents
Lyons, K. E., & Pahwa, R. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00006 · Cited by 235
Use of antihypertensives and the risk of Parkinson disease
Becker, C., Jick, S. S., & Meier, C. R. (2008) · Neurology · doi:10.1212/01.wnl.0000303818.38960.44 · Cited by 230
Nedergaard, S., Flatman, J. A., & Engberg, I. (1993) · The Journal of Physiology · doi:10.1113/jphysiol.1993.sp019742 · Cited by 211
Oxidative and nitrative protein modifications in Parkinson's disease
Danielson, S. R., & Andersen, J. K. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.03.005 · Cited by 202
Morbidity during hospitalization: Can we predict it?
Charlson, M. E., Sax, F. L., Mackenzie, C. R., Braham, R. L., Fields, S. D., & Douglas, R. G. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90107-x · Cited by 169
Grammatopoulos, T. N., Jones, S. M., Ahmadi, F. A., Hoover, B. R., Snell, L. D., Skoch, J., Jhaveri, V. V., Poczobutt, A. M., Weyhenmeyer, J. A., & Zawada, W. M. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-1 · Cited by 165
Tomassoni, D., Lanari, A., Silvestrelli, G., et al. (2008) · Clinical and Experimental Hypertension · doi:10.1080/10641960802580232 · Cited by 148
Kupsch, A. R., Sautter, J., Schwarz, J., Riederer, P. F., Gerlach, M., & Oertel, W. H. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00917-1 · Cited by 110
Muñoz, A., Rey, P., Guerra, M. J., Méndez‐Álvarez, E., Soto‐Otero, R., & Labandeira-García, J. L. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.004 · Cited by 95
Kupsch, A. R., Gerlach, M., Pupeter, S. C., Sautter, J., Dirr, A., Arnold, G., Opitz, W., Przuntek, H., Riederer, P. F., & Oertel, W. H. (1995) · Neuroreport · doi:10.1097/00001756-199503000-00009 · Cited by 87
Uchida, S., Yamada, S., Nagai, K., Deguchi, Y., & Kimura, R. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00881-3 · Cited by 83
Calcium channel blockers and β-blockers in relation to Parkinson's disease
Ton, T. G. N., Heckbert, S. R., Longstreth, W. T., Rossing, M. A., Kukull, W. A., Franklin, G. M., Swanson, P. D., Smith‐Weller, T., & Checkoway, H. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.08.011 · Cited by 51
Louis, E. D., Benito‐León, J., & Bermejo‐Pareja, F. (2009) · Neuroepidemiology · doi:10.1159/000235641 · Cited by 40
USE OF ANTIHYPERTENSIVES AND THE RISK OF PARKINSON DISEASE
Ascherio, A., & Tanner, C. M. (2009) · Neurology · doi:10.1212/01.wnl.0000344171.22760.24 · Cited by 31
Effects of Ca-Antagonists on Oxidative Susceptibility of Low Density Lipoprotein (LDL).
Yoshida, H., Ayaori, M., Suzukawa, M., Hosoai, H., Nishiwaki, M., Ishikawa, T., & Nakamura, H. (1995) · Hypertension Research · doi:10.1291/hypres.18.47 · Cited by 16
A Lethal Convergence of Dopamine and Calcium
Surmeier, D. J. (2009) · Neuron · doi:10.1016/j.neuron.2009.04.010 · Cited by 8
Cited by
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Zamponi, G. W., Striessnig, J., Koschak, A., & Dolphin, A. C. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009654 · Cited by 1,103
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1
Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P. T., & Surmeier, D. J. (2010) · Nature · doi:10.1038/nature09536 · Cited by 843
Determinants of dopaminergic neuron loss in Parkinson's disease
Surmeier, D. J. (2018) · The FEBS Journal · doi:10.1111/febs.14607 · Cited by 444
Metadata
- Authors
- Ritz, B., Rhodes, S. L., Qian, L., Schernhammer, E., Olsen, J. H., & Friis, S.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-04-26
- Volume
- 67
- Issue
- 5
- Pages
- 600-606
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2093288418
- Cited by
- 273
- References
- 24
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.